Apellis Announces Keli Walbert to Join the Board of Directors
Apellis Pharmaceuticals (NASDAQ: APLS) has announced the immediate appointment of Keli Walbert to its Board of Directors, expanding the board to seven members, with six being independent. Walbert brings over 20 years of biopharmaceutical commercial leadership experience, most recently serving as executive vice president of U.S. commercial at Horizon Therapeutics.
In her previous role, Walbert oversaw commercial strategy for more than 10 marketed brands across various therapeutic areas including nephrology, ophthalmology, and rare diseases. She notably led the launch of TEPEZZA, a blockbuster medicine for thyroid eye disease. Her prior experience includes leadership positions at AbbVie, American Medical Association, Abbott, and United Healthcare.
Walbert's appointment aims to strengthen Apellis's commercial expertise as the company continues to expand its geographic atrophy treatment reach and prepares for potential launches in C3G and IC-MPGN indications.
Apellis Pharmaceuticals (NASDAQ: APLS) ha annunciato la nomina immediata di Keli Walbert nel suo Consiglio di Amministrazione, espandendo il consiglio a sette membri, sei dei quali indipendenti. Walbert porta con sé oltre 20 anni di esperienza nel settore commerciale biofarmaceutico, avendo recentemente ricoperto il ruolo di vicepresidente esecutivo per il commercio negli Stati Uniti presso Horizon Therapeutics.
Nel suo ruolo precedente, Walbert ha supervisionato la strategia commerciale per oltre 10 marchi commercializzati in diverse aree terapeutiche, tra cui nefrologia, oftalmologia e malattie rare. Ha guidato in modo particolare il lancio di TEPEZZA, un farmaco di successo per la malattia oculare tiroidea. La sua esperienza precedente include posizioni dirigenziali presso AbbVie, American Medical Association, Abbott e United Healthcare.
La nomina di Walbert mira a rafforzare l'expertise commerciale di Apellis mentre l'azienda continua ad ampliare la sua portata nella cura dell'atrofia geografica e si prepara a potenziali lanci per le indicazioni C3G e IC-MPGN.
Apellis Pharmaceuticals (NASDAQ: APLS) ha anunciado el nombramiento inmediato de Keli Walbert en su Junta Directiva, expandiendo la junta a siete miembros, de los cuales seis son independientes. Walbert aporta más de 20 años de experiencia en liderazgo comercial biofarmacéutico, habiendo ocupado recientemente el cargo de vicepresidenta ejecutiva del comercio en EE. UU. en Horizon Therapeutics.
En su cargo anterior, Walbert supervisó la estrategia comercial de más de 10 marcas comercializadas en diversas áreas terapéuticas, incluyendo nefrología, oftalmología y enfermedades raras. Destacó en el lanzamiento de TEPEZZA, un medicamento exitoso para la enfermedad ocular tiroidea. Su experiencia previa incluye posiciones de liderazgo en AbbVie, Asociación Médica Americana, Abbott y United Healthcare.
El nombramiento de Walbert tiene como objetivo fortalecer la experiencia comercial de Apellis mientras la empresa continúa ampliando su alcance en el tratamiento de la atrofia geográfica y se prepara para posibles lanzamientos en las indicaciones C3G e IC-MPGN.
Apellis Pharmaceuticals (NASDAQ: APLS)는 Keli Walbert를 이사로 즉시 임명했다고 발표하며 이사회가 총 7명의 구성원으로 확장되었고, 그 중 6명은 독립적인 인사라고 전했습니다. Walbert는 최근 Horizon Therapeutics의 미국 상업 부문 부사장을 역임하며 20년 이상의 생물제약 상업 리더십 경험을 가지고 있습니다.
이전 역할에서 Walbert는 신장학, 안과 및 희귀 질환을 포함한 다양한 치료 분야에서 10개 이상의 마케팅 브랜드에 대한 상업 전략을 감독했습니다. 그녀는 갑상선 안구병에 대한 주력 약물 TEPEZZA의 출시를 주도했습니다. 그녀의 이전 경력으로는 AbbVie, 미국 의학 협회, Abbott 및 유나이티드 헬스케어에서의 리더십 직책이 포함됩니다.
Walbert의 임명은 Apellis의 상업 전문성을 강화하기 위한 것으로, 회사가 지리적 위축 치료의 범위를 계속 확장하고 C3G 및 IC-MPGN 적응증에서의 잠재적 출시를 준비하고 있습니다.
Apellis Pharmaceuticals (NASDAQ: APLS) a annoncé la nomination immédiate de Keli Walbert au sein de son Conseil d'Administration, élargissant ce dernier à sept membres, dont six sont indépendants. Walbert apporte plus de 20 ans d'expérience en leadership commercial dans le secteur biopharmaceutique, ayant récemment occupé le poste de vice-présidente exécutive du commerce aux États-Unis chez Horizon Therapeutics.
Dans son rôle précédent, Walbert a supervisé la stratégie commerciale de plus de 10 marques commercialisées dans divers domaines thérapeutiques, notamment en néphrologie, ophtalmologie et maladies rares. Elle a notamment dirigé le lancement de TEPEZZA, un médicament à succès pour la maladie oculaire thyroïdienne. Son expérience antérieure inclut des postes de direction chez AbbVie, l'Association Médicale Américaine, Abbott et United Healthcare.
La nomination de Walbert vise à renforcer l'expertise commerciale d'Apellis alors que l'entreprise continue d'élargir sa portée dans le traitement de l'atrophie géographique et se prépare à d'éventuels lancements dans les indications C3G et IC-MPGN.
Apellis Pharmaceuticals (NASDAQ: APLS) hat die sofortige Ernennung von Keli Walbert in seinen Vorstand bekannt gegeben und den Vorstand auf sieben Mitglieder erweitert, von denen sechs unabhängig sind. Walbert bringt über 20 Jahre Erfahrung in der kommerziellen Führung im biopharmazeutischen Bereich mit, zuletzt als Executive Vice President für den US-Vertrieb bei Horizon Therapeutics.
In ihrer vorherigen Rolle überwachte Walbert die kommerzielle Strategie für mehr als 10 vermarktete Marken in verschiedenen therapeutischen Bereichen, darunter Nephrologie, Augenheilkunde und seltene Krankheiten. Besonders hervorzuheben ist ihre Leitung des Launchs von TEPEZZA, einem Blockbuster-Medikament gegen die Augenkrankheit der Schilddrüse. Zu ihren früheren Erfahrungen gehören Führungspositionen bei AbbVie, der American Medical Association, Abbott und United Healthcare.
Walberts Ernennung soll die kommerzielle Expertise von Apellis stärken, während das Unternehmen seine Reichweite in der Behandlung von geografischer Atrophie weiter ausbaut und sich auf potenzielle Markteinführungen in den Indikationen C3G und IC-MPGN vorbereitet.
- Board expansion strengthens commercial expertise with experienced industry executive
- Addition of leader with proven track record in successful drug commercialization
- Strategic enhancement of leadership team ahead of potential new product launches
- None.
WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms. Walbert brings more than two decades of biopharmaceutical commercial leadership experience to the Board.
“We are delighted to welcome Keli to the Apellis Board of Directors,” said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. “Keli has a proven track record of successfully bringing novel medicines to patients as well as a respected reputation among industry leaders for her strategic thinking and innovation. Her deep commercial expertise will be invaluable as we continue to reach more patients with geographic atrophy and prepare for a potential launch in C3G and IC-MPGN.”
Ms. Walbert most recently served as executive vice president, U.S. commercial, at Horizon Therapeutics, where she was responsible for driving commercial strategy and organizational development for more than 10 marketed brands across nephrology, ophthalmology, and rare disease, among other therapeutic areas. Prior to this position, Ms. Walbert held numerous roles of increasing responsibility at Horizon, including leading the launch of the blockbuster medicine TEPEZZA for thyroid eye disease. Before joining Horizon, Ms. Walbert held leadership roles at AbbVie, American Medical Association, Abbott, and United Healthcare.
“It is an honor to join this exceptional leadership team at Apellis and support the company’s mission to deliver life-changing therapies for some of the world’s most challenging diseases,” said Ms. Walbert. “I am inspired by the company’s scientific innovation and commitment to patients, and I look forward to leveraging my experience as we work to bring these important therapies to those in need.”
Ms. Walbert has received numerous awards and recognitions including the Luminary Award from the Healthcare Businesswomen’s Association and the MM+M Women of Distinction Award. She received a master’s degree from Northwestern University and a bachelor of the arts degree from University of Louisville.
Ms. Walbert’s appointment expands the Board to seven directors, six of whom are independent.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on X and LinkedIn.
Apellis Forward-Looking Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors discussed in the “Risk Factors” section of Apellis’ Annual Report on Form 10-K with the Securities and Exchange Commission on February 27, 2024 and Quarterly Report on Form 10-Q filed on November 5, 2024 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Media Contact:
Lissa Pavluk
media@apellis.com
617.977.6764
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
FAQ
Who is the new board member appointed to Apellis Pharmaceuticals (APLS)?
How many directors are now on the Apellis (APLS) board after Walbert's appointment?
What therapeutic areas will Keli Walbert's experience benefit for Apellis (APLS)?
What significant commercial achievement did Keli Walbert accomplish at Horizon Therapeutics before joining APLS?
